Literature DB >> 14757530

Oncogenes as therapeutic targets.

Dean W Felsher.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14757530     DOI： 10.1016/j.semcancer.2003.11.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


× No keyword cloud information.
  3 in total

1.  NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1).

Authors:  Thomas S Dexheimer; Steven S Carey; Song Zuohe; Vijay M Gokhale; Xiaohui Hu; Lauren B Murata; Estelle M Maes; Andrzej Weichsel; Daekyu Sun; Emmanuelle J Meuillet; William R Montfort; Laurence H Hurley
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

2.  Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Authors:  Catherine M Shachaf; Omar D Perez; Sawsan Youssef; Alice C Fan; Sailaja Elchuri; Matthew J Goldstein; Amy E Shirer; Orr Sharpe; Joy Chen; Dennis J Mitchell; Maria Chang; Garry P Nolan; Lawrence Steinman; Dean W Felsher
Journal:  Blood       Date:  2007-07-10       Impact factor: 22.113

3.  STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.

Authors:  B C Bisikirska; S J Adam; M J Alvarez; P Rajbhandari; R Cox; C Lefebvre; K Wang; G E Rieckhof; D W Felsher; A Califano
Journal:  Oncogene       Date:  2012-11-26       Impact factor: 9.867
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.